Venus Concept Gains FDA Clearance for Venus Nova

An update from Venus Concept ( (VERO) ) is now available.

On November 10, 2025, Venus Concept announced it received 510(k) clearance from the FDA to market Venus Nova, its new multi-application platform for non-invasive treatments. The announcement is part of the company’s strategic efforts to stabilize and grow its business amidst challenging market conditions. Despite a decline in total revenue for the third quarter of 2025, the company reported stabilization in its Energy Based Device revenues and executed significant debt-to-equity exchanges to strengthen its financial position. The company is also working to close the sale of its Venus Hair Business, facing challenges that have led to seeking court assistance.

The most recent analyst rating on (VERO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Venus Concept stock, see the VERO Stock Forecast page.

Spark’s Take on VERO Stock

According to Spark, TipRanks’ AI Analyst, VERO is a Neutral.

Venus Concept’s stock score is primarily impacted by its poor financial performance, characterized by declining revenues, high leverage, and substantial net losses. Technical analysis and valuation metrics further contribute to the low score, reflecting bearish trends and poor valuation. The earnings call provides some positive strategic developments, but significant challenges remain, leading to an overall low stock score.

To see Spark’s full report on VERO stock, click here.

More about Venus Concept

Venus Concept Inc. is a global leader in the medical aesthetic technology industry, specializing in non-invasive body and skin treatments. The company focuses on developing advanced platforms and systems for aesthetic procedures, with a market emphasis on innovative solutions for skin and body care.

Average Trading Volume: 624,600

Technical Sentiment Signal: Strong Sell

Current Market Cap: $3.48M

For a thorough assessment of VERO stock, go to TipRanks’ Stock Analysis page.